Jane Stewart:
The neurobiology of drug use and relapse: thoughts on using what we know to
develop treatments
Ferdinando Nicoletti:
Metabotropic glutamate receptors: beyond the regulation of synaptic
transmission
Symposium 1
Impaired behavioural inhibition in schizophrenia: Implications for antipsychotic
drug development
Organizers: Anton Bespalov, Richard Beninger
Mark Geyer (CA, USA):
Acoustic startle habituation deficits: Phenotypic markers for information-processing
impairment in schizophrenia and efficacy of antipsychotic drug treatment?
Anton Bespalov (Ludwigshafen, Germany):
Habituation deficits induced by metabotropic glutamate type II receptor blockade:
Reversal by antipsychotic drugs
Richard Beninger (Ontario, Canada):
Molecular mechanisms of incentive learning: possible targets for antipsychotic
drugs
Symposium 2
Forward and reverse genetic approaches to reward and addiction, combined
with: genetics in drug addiction
Organizer: Rainer Spanagel (Germany)
Mary Jeanne Kreek (USA):
Microarray studies on drug-induced changes in gene expression
Judith Homberg
(The Netherlands):
Cocaine’s
mechanisms scrutinized using knockout and mutant rats derived from ENU-driven
target-selected mutagenesis
Carles Sanchis-Segura (Spain):
Genetic dissection of glutamate signalling in cocaine sensitization and reward
using conditional mouse models
Karen K. Szumlinski (USA):
The use of virus-mediated gene transfer in drug abuse research
Symposium 3
Novel and emerging therapeutic approaches for the treatment of psychosis
Organizer: Will Spooren
R. Depoortere (France):
Marrying the DA D2 and 5-HT1A receptors: ideal partners for a new generation
of antipsychotics with improved benefit for cognition?
K. Drescher (Germany):
A new twist to novel atypical antipsychotics: dopamine D3 receptor antagonism
R Nordquist (Schweiz):
The behavioural profile of NK3 receptor antagonists: a new generation of anti-psychotics?
N. Waters (Sweden):
Dopaminergic Stabilizers for the treatment of psychiatric and neurological
disorders
Symposium 4
Commonalities and differences in the neurobehavioral mechanisms underlying
drug addiction and obesity
Organizer: Louk J.M.J. Vanderschuren
Gaetano. Di Chiara (Italy):
Drug and food addiction: a case of homology?
Gary Aston-Jones
(South Carolina, USA):
The insidious hypothalamus: obesity, addiction and orexin neurons
Ralph J. DiLeone
(Texas):
Novel molecular and neural mechanisms regulating food and drug intake
David N. Stephens
(Brighton, UK):
Behavioural sensitization to food and drugs:
similarities, but differences, too
Symposium 5
Psychopharmacology of phosphodiesterase inhibitors
Organizer: Thomas Steckler (Beerse, Belgium), Bruno Pouzet
Schmidt, Christopher J. (USA):
PDE10 inhibitors and striatal activity
Siegel, Steven J. (USA):
Overview on “PDEs inhibitors for treatment of schizophrenia”
Prickaerts, Jos (Netherlands):
PDE2 and 5 inhibitors and cognitive function
O’Donnell,
James M. (USA):
PDE4 inhibitors and depression
Symposium 6
Cannabinoid modulation of cognitive processes
Organizer: Jacques Micheau (France), Gernot Riedel (UK)
Paola Fadda (Italy):
Plant-cannabinoid extracts modulate spatial short-term memory
Gernot Riedel (Scotland):
Differential role of hippocampal cannabinoid receptors in spatial memory formation
Robert Hampson (North Carolina):
Cannabinoids alter neuronal representation of task-specific information
Jonathan Arnold (Australia):
Neural and behavioural effects of delta-9 tetrahydrocannabinol in a putative
transgenic mouse model of schizophrenia
Symposium 7
Behavioural pharmacology in pain
Organizer: Thomas Tzschentke (Germany)
A. Eschalier (France):
Pain – An overview of underlying mechanisms, symptoms, and treatment
options: from bed to benchside and back
Thomas Christoph (Germany):
Traditional and novel behavioural models to evaluate pain and analgesia in
preclinical studies
Francis Colpaert (France):
Is there a link between analgesia, tolerance and addiction?
Steve Negus (Belmont):
Emotional aspects of pain: Alternative read-outs and novel behavioural procedures
Symposium 8
Behavioural guidance by predicted reward
Organizer: Wolfgang Hauber (Germany)
Garret Stuber (USA):
Rapid dopamine signalling and excitatory synaptic plasticity in the mesolimbic
system following reward learning
Wolfgang Hauber (Germany):
Role of prefrontal cortex and ventral striatum in guidance of instrumental
behaviour by expected reward
David Belin (UK):
Instrastriatal mechanisms underlie drug-seeking habits maintained
by drug-associated stimuli
Peter Kalivas (USA):
Neuroadaptations in corticolimbic circuitry by chronic cocaine: Effects on
processing biological and drug reward
Symposium 9
Orexin and Melanin Concentrating Hormone – more than feeding alone
Organizer: Bart A. Ellenbroek (Germany)
Pierre Yves Risold (Besancon, France):
Functional
neuroanatomy of the diencephalic MCH and ORX neuronal systems
in the rat brain
Jean Louis Nahon (Valbonne, France):
Functional characterisation of MCH and Orexin neurons
Antonello
Bonci (San Francisco, USA):
The role of orexin and MCH in reward
Joram Mul (Utrecht, Netherlands):
Functional characterization of the pro MCH knockout rat
Symposium 10
Behavioral evidence for inverse agonism and constitutive receptor activity
at serotonin 5-HT2 receptors and at opioid receptors
Organizer: John A. Harvey
William P. Clarke (USA):
Constitutive activity and inverse agonism in vivo: the rules of the game
Vincent Aloyo
(USA):
Regulation of 5-HT2A receptor constitutive activity by behaviourally defined
agonists, antagonists and inverse agonists
Umberto Spampinato (France):
5-HT2C receptor constitutive activity regulates in vivo DA release: focus on
the mesoaccumbens dopamine pathway
Alice M. Young (Texas):
Do inverse agonists play a role in opioid abstinence in vivo?
Symposium 11
Translational medicine in CNS research
Organizer: Robert McArthur
T.W. Robbins (UK):
Translational models of cognitive function
B. Ellenbroek
(Germany):
Translational approaches in the treatment of schizophrenia:
a preclinical approach
T. Steckler (Belgium):
Translational models of anxiety disorders
Bill Deakin (UK):
Translational models in schizophrenia: a clinical view
Symposium 12
Dopamine D2 receptors in Obsessive Compulsive Disorders
Organizer: Aldo Badiani
John Salamone (USA):
Nucleus accumbens DA and the persistent exertion of effort in food-seeking
behavior
Henry Szechtman (Canada):
Modulation by kappa opioid receptors of compulsive checking in the quinpirole
model of obsessive-compulsive disorder (OCD)
Paolo Nencini (Italy):
Quinpirole-induced perseverative drinking: implications for psychotic polydipsia
Damiaan Denys (The Netherlands):
Dopamine and obsessive compulsive disorder: What clinical evidence do we have?
Symposium 13
Pharmacokinetic/pharmacodynamic relationship in psychopharmacology
Organizer: Thomas Steckler (Belgium)
Meindert Danhof (Netherlands):
Pharmacokinetic-pharmacodynamic correlations in psychopharmacology
Jean-Michel Sherrmann (France):
Role of transporters at the blood-brain-barrier in determining cerebral exposure
to psychotropic drugs
Gerald Zernig (Austria):
Measurement of drug concentrations and neurotransmitter release using microdialysis
in rats – relationship to operant responding
Mark Schmidt (Belgium):
Using PET imaging to predict PK/PD relationships of novel psychoactive drugs
in human
Symposium 14
The neuropharmacology of social behaviour
Organizer: Klaus A. Miczek
Francesca D’Amato
(Italy):
Behavioural pharmacology of maternal behaviour/mother-pup interactions
Zuoxin Wang (Florida):
Dopamine and social attachment
K.A. Miczek (USA):
GABA-5HT interactions in aggressive behaviour
L.J.M.J. Vanderschuren (Netherlands):
The neuropharmacology of social play behavior in rats: insights into social
reward mechanisms